Identification of Methotrexate as a Heterochromatin-Promoting Drug

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-48137-w
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Fission Yeast CENP-B Homologs Nucleate Centromeric Heterochromatin by Promoting Heterochromatin-Specific Histone Tail Modifications

Genes and Development
GeneticsDevelopmental Biology
2002English

Identification of Cephalomannine as a Drug Candidate for Glioblastoma via High-Throughput Drug Screening

Journal of Electrophoresis
2018English

Identification of a Phenanthrene Derivative as a Potent Anticancer Drug With Pim Kinase Inhibitory Activity

Cancer Science
Cancer ResearchMedicineOncology
2011English

Drug-Induced Leukoencephalopathy: MR Follow-Up After Methotrexate Therapy

2019English

Telomerase as a Growth-Promoting Factor

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2003English

The Clinical Importance of Drug Monitoring: Methotrexate-Induced Acute Renal Failure

Journal of Pharmacovigilance
2018English

Pneumocystis Carinii Pneumonia as a Complication of Methotrexate Treatment of Asthma.

Thorax
PulmonaryRespiratory Medicine
1991English

Identification of IGF2 Signaling Through Phosphoinositide-3-Kinase Regulatory Subunit 3 as a Growth-Promoting Axis in Glioblastoma

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2007English

Polyvalent Dendrimer-Methotrexate as a Folate Receptor-Targeted Cancer Therapeutic

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy